A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Study Summary

This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).

Conditions

Lupus Nephritis Primary Membranous Nephropathy

Interventions / Drugs

NKX019 Fludarabine, Cyclophosphamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment96 participants

Primary Completion—

Lead SponsorNkarta, Inc.

Data Retrieved2026-04-11 04:22:44.430485+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.